3-[2-(dimethylamino)ethoxy]-2-phenyl-4-quinolinecarboxylicacid, 2-(methoxycarbonyl)-2-phenylhydrazide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 3-[2-(dimethylamino)ethoxy]-2-phenyl-4-quinolinecarboxylicacid, 2-(methoxycarbonyl)-2-phenylhydrazide
• 英文别名: 3-[2-(Dim ethylamino)ethoxy]-2-phenyl-4-quinolinecarboxylic acid, 2-(methoxycarbonyl)-2-phenylhydrazide；methyl N-[[3-[2-(dimethylamino)ethoxy]-2-phenylquinoline-4-carbonyl]amino]-N-phenylcarbamate
• 化学式: C₂₈H₂₈N₄O₄
• 分子量: 484.555
• InChiKey: XCCMZNKLKPVPJT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  36
• 可旋转键数：
  8
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  84
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  methyl 2-{[3-(2-methoxy-2-oxoethoxy)-2-phenylquinolin-4-yl]carbonyl}-1-phenylhydrazinecarboxylate 在 锂硼氢 、 四溴化碳 、 三苯基膦 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 生成 3-[2-(dimethylamino)ethoxy]-2-phenyl-4-quinolinecarboxylicacid, 2-(methoxycarbonyl)-2-phenylhydrazide
  参考文献：
  名称：

  N′,2-Diphenylquinoline-4-carbohydrazide based NK3 receptor antagonists II

  摘要：

  Introduction of selected amine containing side chains into the 3-position of N',2-diphenylquinoline-4-carbohydrazide based NK3 antagonists abolishes unwanted hPXR activation. Introduction of a fluorine at the 8-position is necessary to minimize unwanted hIK(r) affinity and a piperazine N-tert-butyl group is necessary for metabolic stability. The lead compound (8m) occupies receptors within the CNS following oral dosing (Occ(90) 7 mg/kg po; plasma Occgo 0.4 mu M) and has good selectivity and excellent PK properties. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.08.085

文献信息

• Quinoline Derivatives as Neurokinin Receptor Antagonists
  申请人：Carling Robert William

  公开号：US20080096885A1

  公开（公告）日：2008-04-24

  The present invention relates to substituted quinoline-4-carboxylic acid hydrazides defined herein, pharmaceutical compositions comprising them and their use in treating diseases mediated by neurokinin-2 and/or neurokinin-3 (NK-3) receptors.

  本发明涉及在此定义的取代的喹啉-4-羧酸肼类化合物、包含它们的制药组合物以及它们在治疗通过神经激肽-2和/或神经激肽-3（NK-3）受体介导的疾病中的应用。
• [EN] QUINOLINE DERIVATIVES AS NEUROKININ RECEPTOR ANTAGONISTS<br/>[FR] DERIVES DE QUINOLINE SERVANT D'ANTAGONISTES DE RECEPTEURS DE NEUROKININE
  申请人：MERCK SHARP & DOHME

  公开号：WO2006013393A3

  公开（公告）日：2006-04-20
• N′,2-Diphenylquinoline-4-carbohydrazide based NK3 receptor antagonists II
  作者：Jason M. Elliott、Robert W. Carling、Gary G. Chicchi、James Crawforth、Peter H. Hutson、A. Brian Jones、Sarah Kelly、Rose Marwood、Georgina Meneses-Lorente、Elena Mezzogori、Fraser Murray、Michael Rigby、Inmaculada Royo、Michael G.N. Russell、Duncan Shaw、Bindi Sohal、Kwei Lan Tsao、Brian Williams

  DOI：10.1016/j.bmcl.2006.08.085

  日期：2006.11

  Introduction of selected amine containing side chains into the 3-position of N',2-diphenylquinoline-4-carbohydrazide based NK3 antagonists abolishes unwanted hPXR activation. Introduction of a fluorine at the 8-position is necessary to minimize unwanted hIK(r) affinity and a piperazine N-tert-butyl group is necessary for metabolic stability. The lead compound (8m) occupies receptors within the CNS following oral dosing (Occ(90) 7 mg/kg po; plasma Occgo 0.4 mu M) and has good selectivity and excellent PK properties. (c) 2006 Elsevier Ltd. All rights reserved.